06 August 2026 | News
Image Courtesy: Public Domain
LataMed AI Corp. (OTC: LMED) (“LataMed AI” or the “Company”), a healthcare technology company developing digital health and artificial intelligence solutions for Latin America, announced that, through its Venezuelan operating subsidiary LATAMEDAI VE, it will participate in Artificial Intelligence & Health Markets 2026, an educational conference scheduled for August 13 and 14, 2026, at Universidad Santa Maria in Caracas.
The event is expected to bring together students, faculty members, and participants from the university’s systems engineering and healthcare-related academic communities, including pharmacy, dentistry, and laboratory sciences, to examine practical applications of artificial intelligence and automation across medical and technical environments.
LataMed AI will be represented by Dr. Kevin Rodan Levy, Chief Executive Officer, and Carlos Pena, Chief Financial Officer. Their presentation is expected to address the evolving role of artificial intelligence in healthcare, systems engineering, digital infrastructure, and professional decision-making.
During the conference, LataMed AI intends to discuss how artificial intelligence-supported tools may assist healthcare professionals with medical-data evaluation, clinical workflows, and operational decision-making. The Company also plans to examine how automation may support the organization, reliability, and efficiency of technology systems used in healthcare and other complex operating environments.
The presentation will emphasize the importance of maintaining qualified professional oversight when implementing artificial intelligence. LataMed AI’s technologies are intended to enhance human capabilities and support informed decision-making rather than replace the independent judgment of healthcare professionals, engineers, laboratory personnel, or other qualified individuals.
Additional conference topics are expected to include the integration of artificial intelligence and automation into existing systems, responsible data use, privacy and information security, operational risk management, and the practical considerations involved in developing and deploying technology in healthcare settings.
LataMed AI also intends to discuss the continued development of its healthcare technology ecosystem and the role of CardioAI, PulmoAI, and NeuroAI within the Company’s broader strategy. These artificial intelligence-supported platforms are being developed to assist healthcare professionals in the evaluation and management of cardiovascular, pulmonary, and neurological health information, subject to continued development, testing, applicable regulatory requirements, and commercial implementation.
“Artificial Intelligence & Health Markets 2026 provides an important opportunity to engage directly with students, educators, and future professionals who will help shape the responsible use of artificial intelligence in healthcare and systems engineering,” said Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp. “Our objective is to share practical perspectives on how intelligent technologies can support professional decision-making, improve digital workflows, and contribute to the continued development of healthcare infrastructure in Latin America.”
Management believes that engagement with universities and educational institutions can help increase awareness of emerging healthcare technologies, encourage responsible discussion regarding artificial intelligence, and strengthen relationships with future healthcare, engineering, laboratory, and technology professionals.
The Company also views its participation as an opportunity to better understand the perspectives of students, educators, researchers, and technical professionals as it continues developing digital health and artificial intelligence-supported solutions for the Latin American market.
LataMed AI’s participation at Universidad Santa Maria is consistent with its broader strategy of supporting education, professional collaboration, and the responsible adoption of digital healthcare infrastructure throughout the region. The Company intends to continue evaluating opportunities to participate in academic, healthcare, and technology forums that align with its business and educational objectives.
Participation in the conference does not constitute an endorsement of LataMed AI or its technologies by Universidad Santa Maria. The event does not guarantee future research collaborations, employment arrangements, commercial relationships, technology adoption, regulatory authorization, revenue, or other financial benefits.
